A case of atypical hemolytic uremic syndrome in a second renal transplant

Nicholas A. Zwang*, Bing Ho, Yashpal S. Kanwar, Brad Lewis, Matthew Cusick, John J. Friedewald, Lorenzo Gallon

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalJournal of Nephrology
Volume31
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Allografts
Transplants
Kidney
Acute Kidney Injury
Renal Insufficiency
Tissue Donors
Mutation
Antibodies
Atypical Hemolytic Uremic Syndrome
eculizumab

Keywords

  • Atypical hemolytic uremic syndrome
  • Complement biology
  • Graft failure
  • Histocompatibility
  • Kidney transplantation

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{afbac44dc5314dae9242aded766b5ddc,
title = "A case of atypical hemolytic uremic syndrome in a second renal transplant",
abstract = "Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.",
keywords = "Atypical hemolytic uremic syndrome, Complement biology, Graft failure, Histocompatibility, Kidney transplantation",
author = "Zwang, {Nicholas A.} and Bing Ho and Kanwar, {Yashpal S.} and Brad Lewis and Matthew Cusick and Friedewald, {John J.} and Lorenzo Gallon",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s40620-016-0373-7",
language = "English (US)",
volume = "31",
pages = "165--172",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",
number = "1",

}

A case of atypical hemolytic uremic syndrome in a second renal transplant. / Zwang, Nicholas A.; Ho, Bing; Kanwar, Yashpal S.; Lewis, Brad; Cusick, Matthew; Friedewald, John J.; Gallon, Lorenzo.

In: Journal of Nephrology, Vol. 31, No. 1, 01.02.2018, p. 165-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case of atypical hemolytic uremic syndrome in a second renal transplant

AU - Zwang, Nicholas A.

AU - Ho, Bing

AU - Kanwar, Yashpal S.

AU - Lewis, Brad

AU - Cusick, Matthew

AU - Friedewald, John J.

AU - Gallon, Lorenzo

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.

AB - Atypical hemolytic uremic syndrome (aHUS) has gained increased visibility over several years as an important cause of renal failure. Unfortunately, diagnosis is often difficult because individual courses can be highly variable depending the causative genetic mutations. Here we present the case of a patient with a failed renal allograft and acute failure of a second allograft who was ultimately diagnosed with aHUS. Interestingly, he developed early de novo donor specific antibodies (DSA) after the second renal transplant in context of likely recurrent aHUS. Terminal complement inhibition with eculizumab resulted in prompt improvement of renal allograft function.

KW - Atypical hemolytic uremic syndrome

KW - Complement biology

KW - Graft failure

KW - Histocompatibility

KW - Kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=85034663580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034663580&partnerID=8YFLogxK

U2 - 10.1007/s40620-016-0373-7

DO - 10.1007/s40620-016-0373-7

M3 - Article

C2 - 28224376

AN - SCOPUS:85034663580

VL - 31

SP - 165

EP - 172

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 1

ER -